FDA gets mixed feedback on performance monitoring for AI | MedTech Dive
The lobbying group said that locked AI models, which don't change autonomously over time, may carry lower risk and not require postmarket monitoring.
Read the original at MedTech Dive ↗
- Topics
- Healthcare
- Mentions
- FDA
- Tracked via
- “AI Risks”